The use of risk-directed chemotherapy for childhood acute lymphoblastic leu- kemia (ALL) has improved the success of therapy dramatically in the last 40 years; however, a substantial proportion of patients experience relapse and many of these have no known risk factors. There- fore, more accurate risk classification of newly diagnosed disease is needed to reduce relapses and improve the overall outcome. This study by Yang et al. aimed at agnostically testing, with a genome- wide approach, genotypes at 444,044 SNPs for their association with the risk of relapse in 2535 children with newly diagnosed ALL, the largest group of chil- dren with cancer ever studied for genetic determinants of outcome [1]. Germline DNA was collected at remission in chil- dren with ALL treated according to St Jude Children’s Research Hospital (TN, USA) Total XIIIB and XV protocols and the Children’s Oncology Group (COG) P9906 or P9904/9905 studies [2]. Relapse was defined as disease recurrence in bone marrow and/or extramedullary sites.

Systematic identification of host genomic variation related to treatment outcome of childhood acute lymphoblastic leukemia

STOCCO, GABRIELE;FRANCA, RAFFAELLA;LONDERO, MARGHERITA;DECORTI, GIULIANA
2013-01-01

Abstract

The use of risk-directed chemotherapy for childhood acute lymphoblastic leu- kemia (ALL) has improved the success of therapy dramatically in the last 40 years; however, a substantial proportion of patients experience relapse and many of these have no known risk factors. There- fore, more accurate risk classification of newly diagnosed disease is needed to reduce relapses and improve the overall outcome. This study by Yang et al. aimed at agnostically testing, with a genome- wide approach, genotypes at 444,044 SNPs for their association with the risk of relapse in 2535 children with newly diagnosed ALL, the largest group of chil- dren with cancer ever studied for genetic determinants of outcome [1]. Germline DNA was collected at remission in chil- dren with ALL treated according to St Jude Children’s Research Hospital (TN, USA) Total XIIIB and XV protocols and the Children’s Oncology Group (COG) P9906 or P9904/9905 studies [2]. Relapse was defined as disease recurrence in bone marrow and/or extramedullary sites.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2662115
 Avviso

Registrazione in corso di verifica.
La registrazione di questo prodotto non è ancora stata validata in ArTS.

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact